Binds Virus Or Component Or Product Thereof (e.g., Virus-associated Antigen, Etc.) Patents (Class 530/388.3)
  • Patent number: 9395286
    Abstract: Trapping devices and methods are provided for capturing a medical analyte, in blood or another biological fluid. The device may include a structural substrate and a binding agent, such as an antibody, affixed to the structural substrate, wherein the binding agent is capable of binding or attaching with a medical analyte, such as a viral particle, and the device is configured for placement in a biological cavity or vessel (containing a biological fluid) in a patient. The trapping device, which may be in a twisted coil shape, is configured to trap at least some of the medical analyte, such a viral particle, present in the biological fluid. The method may include deploying a trapping device into the patient's blood vessel; after a period following the deployment, removing the trapping device from the biological cavity or blood vessel; and then analyzing the trapping device for the presence of the medical analyte.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: July 19, 2016
    Assignees: Massachusetts Institute of Technology, Lahey Clinic Foundation, Inc.
    Inventors: Michael J. Cima, Gregory J. Ekchian, Christophoros C. Vassiliou, Vincent H. Liu, Christoph Wald, Sebastian Flacke, Fredric D. Gordon
  • Patent number: 9145454
    Abstract: Described herein are a number of Ebola monoclonal antibodies.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: September 29, 2015
    Assignee: Her Majesty the Queen in the Right of Canada as Represented by the Minister of Health
    Inventors: Steven Jones, Xiangguo Qiu, Heinz Feldmann, Ute Stroeher
  • Publication number: 20150104466
    Abstract: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.
    Type: Application
    Filed: October 16, 2013
    Publication date: April 16, 2015
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Teresa Compton, Adam L. Feire
  • Publication number: 20150098948
    Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 9, 2015
    Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
  • Patent number: 8992929
    Abstract: The present invention relates to the murine monoclonal antibody 4C2 or to chimeric or humanized monoclonal antibodies specific to a major neutralizing epitope of influenza H5 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using such murine or chimeric or humanized monoclonal antibodies or fragments thereof.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: March 31, 2015
    Assignee: Temasek Life Sciences Laboratory Limited
    Inventors: Prabakaran Mookkan, Fang He, Hwei-Sing Jimmy Kwang
  • Publication number: 20150086973
    Abstract: A monoclonal antibody against the Duck Tembusu virus and a hybridoma cell line secreting the monoclonal antibody, a reagent kit and method for detecting a Duck Tembusu virus antibody, and application of the monoclonal antibody in preparing products for diagnosing the Duck Tembusu virus disease. The monoclonal antibody may bind specifically to E protein of Duck Tembusu virus and has an activity of neutralizing Duck Tembusu virus.
    Type: Application
    Filed: May 16, 2012
    Publication date: March 26, 2015
    Applicant: SHANGHAI VETERINARY RESEARCH INSTITUTE, CAAS
    Inventors: Zejun Li, Xuesong Li
  • Patent number: 8986686
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 24, 2015
    Assignee: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Publication number: 20150079581
    Abstract: The present invention is a test kit for rapidly diagnosing influenza according to the principles of immunochromatography, and the purpose thereof is to provide a test kit for the influenza A virus in which the sensitivity in detecting the influenza A virus is greater than in conventional test kits, and a determination of “positive” is obtained stably and with high precision at an earlier time during the onset of influenza symptoms. The present invention pertains to a kit for detecting influenza A virus, in which an antibody that is in solid phase in the chromatographic medium enters into an antigen-antibody reaction with native nuclear proteins of the influenza A virus, but in Western blots the antibody does not enter into antigen-antibody reactions with full-length nuclear proteins of the influenza A virus that have been separated using SDS-polyacrylamide gel electrophoresis.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 19, 2015
    Inventors: Hisahiko Iwamoto, Hiroko Kawamoto, Shinichi Kato
  • Patent number: 8975378
    Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: March 10, 2015
    Assignees: Osaka University, The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
  • Patent number: 8975036
    Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: March 10, 2015
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
  • Publication number: 20150056188
    Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 26, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: Kenneth Simon, Thomas Cameron, Mia Rushe, Justin Caravella, George Campbell Kaynor
  • Patent number: 8962810
    Abstract: The present invention discloses a class of novel macro-heterocyclic compounds represented by the formula Ia or Ib, and their intermediates, preparation methods and the uses. The macro-heterocyclic compounds of the present invention have good inhibitory activities against hepatitis C virus (HCV), and can be used to treat HCV infection effectively by its excellent inhibition against HCV, low toxicity and side effects.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: February 24, 2015
    Assignee: AB Pharma Ltd.
    Inventor: Zheng-yun James Zhan
  • Patent number: 8961978
    Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: February 24, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
  • Publication number: 20150050271
    Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 19, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: Kenneth Simon, Thomas Cameron, Deping Wang, Joseph Arndt, Mia Rushe, Justin Caravella, Eric Day
  • Patent number: 8945567
    Abstract: Amino acid sequences are provided that are directed against and/or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: February 3, 2015
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Catelijne Stortelers, Stephanie Staelens
  • Patent number: 8900826
    Abstract: A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 2, 2014
    Assignee: University of Maryland, Baltimore
    Inventor: Lai-Xi Wang
  • Patent number: 8900592
    Abstract: The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a heteromultimeric protein, is useful for redirecting an immune response that was pre-existing in a patient, toward an undesired target cell.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: December 2, 2014
    Assignee: Universite de Reims Champagne Ardenne
    Inventors: Jacques Henri Max Cohen, Wael Mahmoud, Marcelle Tonye Libyh, Nathalie Godin, Annelise Gimenez, Thierry Tabary, Beatrice Donvito, Daniel Baty, Xavier Dervillez
  • Publication number: 20140348858
    Abstract: The use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, to a monoclonal antibody IgG2A secreted by the cell line of 8A4/G9 hybridoma specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. The antibodies are in the pure state and do not contain any other contaminating biological material. A method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a given host is provided, including the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease. The antibody can be humanized in order to minimize the possibility of an immune response against the same in the patient.
    Type: Application
    Filed: November 23, 2012
    Publication date: November 27, 2014
    Inventors: Alexis Mikes Kalergis Parra, Susan Marcela Bueno Ramirez, Jorge Eugenio Mora Alarcon, Roberto Sebastian Gomez Johnson
  • Publication number: 20140348851
    Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.
    Type: Application
    Filed: October 18, 2012
    Publication date: November 27, 2014
    Applicants: THE UNIVERSITY OF CHICAGO, EMORY UNIVERSITY
    Inventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
  • Patent number: 8894997
    Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: November 25, 2014
    Assignees: Vanderbilt University, Icahn School of Medicine at Mount Sinai
    Inventors: James E. Crowe, Christopher F. Basler
  • Publication number: 20140328797
    Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 6, 2014
    Inventors: Po-Ying Chan-Hui, III, Kristine Swiderek
  • Patent number: 8877200
    Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: November 4, 2014
    Assignee: Visterra, Inc.
    Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
  • Patent number: 8871207
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 28, 2014
    Assignee: Humabs, LLC
    Inventor: Antonio Lanzavecchia
  • Patent number: 8858947
    Abstract: The present invention provides identification and characterization of conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV). The present invention provides a panel of human monoclonal antibodies that recognize conformational epitopes of E2. The antibodies are derived from patients infected with HCV. The present invention provides methods for utilizing HCV antibodies as therapeutic, diagnostic, and/or prophylactic agents. The present invention provides mimotopes with conformational epitopes intact and methods of using mimotopes. The present invention provides methods of stratifying patients based on their response to HCV. The present invention provides pharmaceutical compositions for prevention and treatment of HCV comprising one or more HCV antibodies.
    Type: Grant
    Filed: October 5, 2008
    Date of Patent: October 14, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Steven Foung, Zhen-yong Keck
  • Publication number: 20140272931
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Application
    Filed: December 23, 2013
    Publication date: September 18, 2014
    Applicant: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • Publication number: 20140275492
    Abstract: The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: MUSC Foundation for Research Development
    Inventors: Natalie SUTKOWSKI, Semyon Rubinchik
  • Publication number: 20140271655
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Application
    Filed: July 18, 2011
    Publication date: September 18, 2014
    Inventor: Antonio Lanzavecchia
  • Patent number: 8828399
    Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 9, 2014
    Assignee: The Trustees of Princeton University
    Inventors: Thomas Shenk, Dai Wang
  • Patent number: 8828400
    Abstract: Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: September 9, 2014
    Assignee: Deutsches Krebsforschungszentrum Siftung des Öffentlichen Rechts
    Inventors: Barbara Leuchs, Kathrin Kürschner, Andrea Kuck, Marcus Müller, Silvia Münstermann, Jean Rommelaere
  • Patent number: 8822651
    Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: September 2, 2014
    Assignee: Theraclone Sciences, Inc.
    Inventor: Po-Ying Chan-Hui
  • Patent number: 8795667
    Abstract: The present invention relates to improved compositions for the prevention and treatment of smallpox, and in particular to the use of compositions containing an antibody that binds to an epitope found on the MV form of the smallpox virus and an antibody that binds to an epitope found on the EV form of the smallpox virus. The invention relates to such compositions, especially to non-blood derived antibody compositions, such as chimeric or humanized antibodies, and to methods for their use in imparting passive immunity against smallpox infection to individuals at risk of smallpox virus infection or who exhibit smallpox.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: August 5, 2014
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Publication number: 20140205615
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 24, 2014
    Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Publication number: 20140193428
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: December 4, 2013
    Publication date: July 10, 2014
    Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Patent number: 8765132
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: July 1, 2014
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 8722341
    Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV). Described are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. Also described is mammalian MPV, subgroups and variants thereof, and genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods is provided. Nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus are described. Also provided are chimeric or recombinant viruses encoded by said nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: May 13, 2014
    Assignees: ViroNovative B.V., MedImmune Vaccines, Inc.
    Inventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Aurelia Haller, Roderick Tang
  • Patent number: 8685402
    Abstract: The invention relates to antibodies and antigen binding fragments thereof, that bind to hemagglutinin and neutralize infection of at least two different group 1 subtypes or at least two different group 2 subtypes of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: April 1, 2014
    Assignee: Institute for Research in Biomedicine
    Inventor: Antonio Lanzavecchia
  • Publication number: 20140079715
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United States of America, as represented by the Secretary, Department of Healt
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
  • Publication number: 20140065599
    Abstract: Provided is a new polyomavirus, provisionally named MX polyomavirus, (MXPyV). Further provided are cDNA nucleic acid sequences, recombinant proteins, expression vectors and host cells, recombinant anti-MXPyV antibodies, vaccines, compositions, methods of detecting MXPyV, methods for assaying for anti-MXPyV compounds, and methods for treating or preventing a MXPyV infection.
    Type: Application
    Filed: August 22, 2013
    Publication date: March 6, 2014
    Inventors: Charles CHIU, Guixia Yu, Alexander Greninger, Pavel Isa, Carlos F. Arias, Joseph De Risi, Juliet Parsonnet, Steve Miller
  • Publication number: 20140065165
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Application
    Filed: October 10, 2013
    Publication date: March 6, 2014
    Applicant: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • Patent number: 8663950
    Abstract: The present invention describes the plant-based production of a therapeutic antibody against West Nile Virus.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 4, 2014
    Assignee: Arizona Board of Regents
    Inventors: Qiang Chen, Huafang Lai
  • Publication number: 20140056913
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Application
    Filed: July 25, 2013
    Publication date: February 27, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Luke Nathaniel Robinson, Kannan Tharakaraman
  • Patent number: 8658354
    Abstract: A method of immunoassay of H5 subtype influenza A virus by which the virus can be accurately assayed even in cases where a certain level of mutation has occurred in the H5 subtype influenza A virus, and a kit therefor, and a novel anti-H5 subtype influenza A virus monoclonal antibody which can be used for the immunoassay are disclosed. The antibody or an antigen-binding fragment thereof of the present invention undergoes antigen-antibody reaction with hemagglutinin of H5 subtype influenza A virus, and the corresponding epitope of the antibody or an antigen-binding fragment thereof is located in a region other than the receptor subdomain (excluding C-terminal region thereof consisting of 11 amino acids), which antibody or an antigen-binding fragment thereof does not have neutralizing activity against the influenza A virus.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: February 25, 2014
    Assignees: National University Corporation Hokkaido University, Fujirebio Inc.
    Inventors: Hiroshi Kida, Yoshihiro Sakoda, Eiji Miyagawa, Nobuyuki Fujii, Yoshiaki Uchida, Takashi Shirakawa, Hiroyuki Kogaki
  • Patent number: 8647818
    Abstract: Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: February 11, 2014
    Assignees: UAB Research Foundation, University of Alabama—Birmingham, The United States of America, as represented by the Secretary, Department of Health and Human Services (Hereinafter the Government) Office of Technology Transfer, National Institutes of Health
    Inventors: George M. Shaw, Beatrice H. Hahn, Frederic Bibollet-Ruche, Peter D. Kwong
  • Patent number: 8648176
    Abstract: The present invention features, inter alia, compositions and methods for the treatment of cancer and infectious disease. The compositions include engineered proteins that specifically bind a metal chelate and may be bispecific. For example, the engineered proteins may bind (a) a target (e.g., a cellular protein) on a cancerous cell or a pathogen and (b) a metal chelate comprising DOTA, or an active variant thereof, and a metal ion such as a radionuclide. By virtue of the multiple binding sites, the engineered protein effectively delivers a metal chelate to a cell one wishes to destroy.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: February 11, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Kelly Davis Orcutt, Karl Dane Wittrup
  • Publication number: 20140037648
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both RSV, MPV and PVM. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to polypeptides that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV or MPV infection and RSV and MPV co-infection.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 6, 2014
    Applicant: HUMABS BIOMED SA
    Inventor: HUMABS BIOMED SA
  • Patent number: 8637644
    Abstract: The invention provides monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes of avian influenza virus (“AIV”). The monoclonal antibodies and related binding proteins are useful for the detection of H5 subtypes of AIV, including the pathogenic H5N1 subtypes. Virus may be detected in formalin preserved, paraffin embedded specimens as well as frozen specimens and biological fluids. Accordingly, the invention provides for the diagnosis and surveillance of dangerous viral infections.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 28, 2014
    Assignee: Temasek Life Sciences Laboratory Limited
    Inventors: Yuen Fern Ho, Qing Yun Du, Fang He, Jimmy Hwei-Sing Kwang
  • Patent number: 8637234
    Abstract: Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: January 28, 2014
    Assignees: UAB Research Foundation, The Administrators of Tulane Educational Fund, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: George M. Shaw, James E. Robinson, Frederic Bibollet-Ruche, Julie M. Decker, Beatrice H. Hahn, Peter D. Kwong
  • Patent number: 8637645
    Abstract: The invention provides monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes of avian influenza virus (“AIV”). The monoclonal antibodies and related binding proteins are useful for the detection of H5 subtypes of AIV, including the pathogenic H5N1 subtypes. Virus may be detected in formalin preserved, paraffin embedded specimens as well as frozen specimens and biological fluids. Accordingly, the invention provides for the diagnosis and surveillance of dangerous viral infections.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 28, 2014
    Assignee: Temasek Life Sciences Laboratory Limited
    Inventors: Yuen Fern Ho, Qing Yun Du, Fang He, Jimmy Hwei-Sing Kwang
  • Publication number: 20130337438
    Abstract: The present invention relates to the development of a monoclonal antibody which has binding activity to many high-risk types of HPV, etc. The present invention also provides a simple and high-throughput method for measuring cross-neutralizing antibody titers, which is used for assay of cross-neutralizing antibody against HPV in serum samples from subjects, etc. The method of the present invention for measuring cross-neutralizing antibody titers comprises the steps of: preparing a monoclonal antibody against a peptide having a specific amino acid sequence common to high-risk types of HPV; and assaying cross-neutralizing antibody using this monoclonal antibody.
    Type: Application
    Filed: December 26, 2011
    Publication date: December 19, 2013
    Applicant: JAPAN HEALTH SCIENCES FOUNDATION
    Inventors: Seiichiro Mori, Tadahito Kanda
  • Patent number: 8603480
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: December 10, 2013
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno